$P

Colgrove John sold $877K of P (indirect holdings)

Colgrove John (Chief Visionary Officer) sold 10,280 indirectly-held shares of Everpure, Inc. (P) at $85.32 ($0.88M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Colgrove John
Published Jun 4, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$P
Neutral
medium confidence
Mentioned
$P
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PNeutralLow
01

Why it matters

The main tradable element is the market’s interpretation of insider behavior. However, 10b5-1 typically reduces informational content versus discretionary selling.

02

Market read

Traders may monitor for follow-on insider activity or other catalysts, but this filing alone is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not disclose reasons for the sale, and 10b5-1 plans often execute regardless of fundamentals; without additional filings or guidance changes, signal quality is low.

Relevance 6/10Novelty 6/10Timing: Filed after-hours/late day (2026-06-04 16:22 ET) for a sale dated 2026-06-02

Background

This is an SEC Form 4 insider transaction disclosure for Everpure, Inc., reporting an open-market sale by an officer/director under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$PNeutralMedium confidence
Context

Everpure insider Form 4 shows Chief Visionary Officer Colgrove John sold 10,280 shares at $85.32 on a 10b5-1 plan, leaving 0 shares.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless accompanied by other fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/M&A/regulatory). The sale is explicitly on a pre-arranged 10b5-1 plan and the holder ends with 0 shares, which can draw attention but is not strong evidence of a new negative catalyst by itself.

Market effects

Minimal; this is company-specific insider activity with no stated operational or sector-wide trigger.

None indicated.

None indicated.

Counterpoint

Because the transaction is on a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity needs rather than bearish information; the market may overreact.

Key entities

  • Everpure, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Colgrove John

    Chief Visionary Officer; sold 10,280 shares at $85.32 under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHighAI 8/10

Everpure (P) Shares Rise After CFRA Upgrade and Strong Fiscal 20

Everpure Inc (NYSE: P) shares rose 3% after CFRA upgraded it from Sell to Buy, citing raised guidance for fiscal 2028. The company projects $7B-$7.3B in revenue and $1.7B-$1.9B in non-GAAP operating income, driven by demand for its all-flash storage solutions in AI data centers. Despite this, GuruFocus's GF Value™ suggests the stock is overvalued at $126.00, with an intrinsic value of $81.40.

$METAMedAI 8/10

Meta, Everpure, Akamai Technologies, Apimeds Pharmaceuticals and Costco: Why These 5 Stocks Are on Invest

Meta (META) rose 4.5% to $777.59, driven by AI strategy. Everpure (P) surged 11.15% to $121.88, reaffirming fiscal 2027 guidance. Akamai (AKAM) fell 6.78% to $110.41, then jumped 20.65% after-hours on a $11.6B AI deal. Apimeds (APUS) soared 114.85% to $4.92 on a blockchain agreement. Costco (COST) dipped 0.91% to $896.48 despite beating Q4 estimates.

$PHighAI 8/10

Everpure Stock Jumps As S&P 500 Inclusion Fuels Momentum

Everpure Inc. (NYSE: P) stock rose 12.77% after its inclusion in the S&P 500. The company's shares have climbed from the low-$90s to $121.88, with a high of $131.41. Everpure reported $3.66B in annual revenue, 70.2% gross margins, and a P/E above 380. The S&P 500 inclusion is expected to drive passive fund buying.

$PMed

Needham raises Everpure stock price target on strong FY28 outlook

Needham raised its price target for Everpure (NYSE:P) to $150 from $140, maintaining a Buy rating. The firm cited Everpure's strong fiscal 2028 outlook, with projected revenue growth of 39% to 45% and operating margins of 24% to 26%. The company also reported second-quarter fiscal 2027 revenue of $1.186 billion, up 38% year-over-year. Several analysts have revised earnings upwards, and the stock has returned 68.3% over the last six months.